Plenary Keynote Program
Base Editing: Chemistry on a Target Nucleotide in the Genome of Living Cells
David R. Liu, PhD, Howard Hughes Medical Institute Investigator, Professor of Chemistry & Chemical Biology, Harvard University
PROTACs: Past, Present, and Future
Craig M. Crews, PhD, Professor, Chemistry; Pharmacology; Molecular, Cellular & Developmental Biology; Yale University
View Details
Featured Speakers
John Doench, PhD
Broad Institute of Harvard and MIT
Bryan Fuchs, PhD
Ferring Research Institute
Nathanael S. Gray, PhD
Dana-Farber Cancer Institute
Stephen J. Haggarty, PhD
Harvard Medical School & Massachusetts General Hospital
Cory M. Hogaboam, PhD
Cedars-Sinai Medical Center
Paul A. Insel, MD
University of California, San Diego
Ian James, PhD
Trevena, Inc.
Elliott Nickbarg, PhD
Merck & Co, Inc.
Andrew Nixon, PhD
Boehringer Ingelheim
J. Brad Shotwell, PhD
AbbVie
Rebecca Taub, MD
Madrigal Pharmaceuticals
Peter M. Tessier, PhD
University of Michigan
Shaomeng Wang, PhD
University of Michigan
Kevin Weeks, PhD
University of North Carolina
About the Event
The 17th Annual Discovery on Target (DOT), the industry’s preeminent event on novel drug targets and technologies, will convene over 1,100 drug discovery professionals in Boston, MA, on September 16-19, 2019. This event
highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules. Delegates
can customize their experience at the event by choosing from 14 conference programs, plus focused training seminars, comprehensive short courses, moderated roundtables and networking functions to meet their own research needs and those of
their organizations.
Additions for 2019 include new programming dedicated to PROTACs and their applications, drugs and targets in fibrosis, novel
immune-oncology targets,
RNA as an emerging target for small molecule drugs, along with expanded coverage of protein engineering and novel biotherapeutics.